2025 Q4 -tulosraportti
66 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,91%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 623 | - | - | ||
| 42 | - | - | ||
| 8 695 | - | - | ||
| 2 483 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
5 t sitten5 t sittenInvesting in Novo Feels like having dead money
·5 t sitten · MuokattuRead along here: https://finans.dk/erhverv/ECE19188477/novo-nordisk-sammenlaegger-to-afdelinger-og-foretager-organisatoriske-tilpasninger/https://medwatch.dk/brancher/Medicinal___Biotek/article19191138.ece Updates will certainly follow in the coming days. It is good that NN informs gradually, so fleet possible investors are informed. The news in question began to circulate last week, i.e. the delay is ~1-2 weeks' time in this case, which is fine.
·5 t sittenIs it permissible to hope that we are now beginning, after such a long time, to see that the bottom is near. Such a large company should recover at some point, one would think, but this fall has been heavy, especially for those who have their pensions invested there.
·6 t sittenI just read an analysis comparing Eli Lilly and Novo Nordisk on a medical and financial level. Link: Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader The analysis addresses next year's guidance and a narrative that many other analyses cover, stating that Novo Nordisk only has CagriSema in its pipeline. I agree that this year will be characterized by several different negative challenges; patent expiry, orforglipron, competition, government influence, and the CagriSema disappointment. However, there are also several positives that analysts and “experts” forget; UBT251 (approximately similar to Ratatutide: triple antagonist (Side effect and effect)), (but excluding the market in China due to TUL’s ownership of the Chinese patent), Sema HD @7.2 mg (approximately similar weight loss to Trizipatide @15 mg), Oral Wegovy @25 mg (decidedly better weight loss and side effect profile than orfoglipron), Amycretin -> Zenagamtide (best in class; effect and side effect profile, with oral and injection) and many more medications (also beyond obesity). In addition, there are many other good reasons such as increased production capacity and infrastructure, acquisitions around cardiovascular diseases, SNAC technology that can bring other peptides to the oral market, relatively high dividend (if the stock rises, the stock will pay out less percentage-wise) and capital returned to investors through share buybacks, low debt (relatively) and good credit rating. Personally, I think things are going well. Many forget that Novo Nordisk was first on the market with semaglutide, and then trizapatide came after. The market is changing and Novo Nordisk will never be far behind Eli Lilly, if they don't surpass them once again. When the market sees the potential of both Eli Lilly and Novo Nordisk as a whole, Novo Nordisk will likely rise nicely and a doubling from the current price could be relevant. In the meantime, we receive dividends and a stock that largely shields us from geopolitical unrest and unpredictability. Not financial advice and all that stuff. If anyone has questions or wants a thorough explanation, I'd be happy to provide it :)- ·9 t sittenso novo is down to 239 in USA⬇️⬇️⬇️
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
66 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,91%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 5 t sitten5 t sittenInvesting in Novo Feels like having dead money
- ·5 t sitten · MuokattuRead along here: https://finans.dk/erhverv/ECE19188477/novo-nordisk-sammenlaegger-to-afdelinger-og-foretager-organisatoriske-tilpasninger/https://medwatch.dk/brancher/Medicinal___Biotek/article19191138.ece Updates will certainly follow in the coming days. It is good that NN informs gradually, so fleet possible investors are informed. The news in question began to circulate last week, i.e. the delay is ~1-2 weeks' time in this case, which is fine.
- ·5 t sittenIs it permissible to hope that we are now beginning, after such a long time, to see that the bottom is near. Such a large company should recover at some point, one would think, but this fall has been heavy, especially for those who have their pensions invested there.
- ·6 t sittenI just read an analysis comparing Eli Lilly and Novo Nordisk on a medical and financial level. Link: Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader The analysis addresses next year's guidance and a narrative that many other analyses cover, stating that Novo Nordisk only has CagriSema in its pipeline. I agree that this year will be characterized by several different negative challenges; patent expiry, orforglipron, competition, government influence, and the CagriSema disappointment. However, there are also several positives that analysts and “experts” forget; UBT251 (approximately similar to Ratatutide: triple antagonist (Side effect and effect)), (but excluding the market in China due to TUL’s ownership of the Chinese patent), Sema HD @7.2 mg (approximately similar weight loss to Trizipatide @15 mg), Oral Wegovy @25 mg (decidedly better weight loss and side effect profile than orfoglipron), Amycretin -> Zenagamtide (best in class; effect and side effect profile, with oral and injection) and many more medications (also beyond obesity). In addition, there are many other good reasons such as increased production capacity and infrastructure, acquisitions around cardiovascular diseases, SNAC technology that can bring other peptides to the oral market, relatively high dividend (if the stock rises, the stock will pay out less percentage-wise) and capital returned to investors through share buybacks, low debt (relatively) and good credit rating. Personally, I think things are going well. Many forget that Novo Nordisk was first on the market with semaglutide, and then trizapatide came after. The market is changing and Novo Nordisk will never be far behind Eli Lilly, if they don't surpass them once again. When the market sees the potential of both Eli Lilly and Novo Nordisk as a whole, Novo Nordisk will likely rise nicely and a doubling from the current price could be relevant. In the meantime, we receive dividends and a stock that largely shields us from geopolitical unrest and unpredictability. Not financial advice and all that stuff. If anyone has questions or wants a thorough explanation, I'd be happy to provide it :)
- ·9 t sittenso novo is down to 239 in USA⬇️⬇️⬇️
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 623 | - | - | ||
| 42 | - | - | ||
| 8 695 | - | - | ||
| 2 483 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
2025 Q4 -tulosraportti
66 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
7,95 DKK/osake
Viimeisin osinko
4,91%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 5 t sitten5 t sittenInvesting in Novo Feels like having dead money
- ·5 t sitten · MuokattuRead along here: https://finans.dk/erhverv/ECE19188477/novo-nordisk-sammenlaegger-to-afdelinger-og-foretager-organisatoriske-tilpasninger/https://medwatch.dk/brancher/Medicinal___Biotek/article19191138.ece Updates will certainly follow in the coming days. It is good that NN informs gradually, so fleet possible investors are informed. The news in question began to circulate last week, i.e. the delay is ~1-2 weeks' time in this case, which is fine.
- ·5 t sittenIs it permissible to hope that we are now beginning, after such a long time, to see that the bottom is near. Such a large company should recover at some point, one would think, but this fall has been heavy, especially for those who have their pensions invested there.
- ·6 t sittenI just read an analysis comparing Eli Lilly and Novo Nordisk on a medical and financial level. Link: Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader The analysis addresses next year's guidance and a narrative that many other analyses cover, stating that Novo Nordisk only has CagriSema in its pipeline. I agree that this year will be characterized by several different negative challenges; patent expiry, orforglipron, competition, government influence, and the CagriSema disappointment. However, there are also several positives that analysts and “experts” forget; UBT251 (approximately similar to Ratatutide: triple antagonist (Side effect and effect)), (but excluding the market in China due to TUL’s ownership of the Chinese patent), Sema HD @7.2 mg (approximately similar weight loss to Trizipatide @15 mg), Oral Wegovy @25 mg (decidedly better weight loss and side effect profile than orfoglipron), Amycretin -> Zenagamtide (best in class; effect and side effect profile, with oral and injection) and many more medications (also beyond obesity). In addition, there are many other good reasons such as increased production capacity and infrastructure, acquisitions around cardiovascular diseases, SNAC technology that can bring other peptides to the oral market, relatively high dividend (if the stock rises, the stock will pay out less percentage-wise) and capital returned to investors through share buybacks, low debt (relatively) and good credit rating. Personally, I think things are going well. Many forget that Novo Nordisk was first on the market with semaglutide, and then trizapatide came after. The market is changing and Novo Nordisk will never be far behind Eli Lilly, if they don't surpass them once again. When the market sees the potential of both Eli Lilly and Novo Nordisk as a whole, Novo Nordisk will likely rise nicely and a doubling from the current price could be relevant. In the meantime, we receive dividends and a stock that largely shields us from geopolitical unrest and unpredictability. Not financial advice and all that stuff. If anyone has questions or wants a thorough explanation, I'd be happy to provide it :)
- ·9 t sittenso novo is down to 239 in USA⬇️⬇️⬇️
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 623 | - | - | ||
| 42 | - | - | ||
| 8 695 | - | - | ||
| 2 483 | - | - |
Välittäjätilasto
Dataa ei löytynyt